Biogen (BIIB)
(Delayed Data from NSDQ)
$217.81 USD
-0.25 (-0.11%)
Updated May 24, 2024 04:00 PM ET
After-Market: $217.88 +0.07 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BIIB 217.81 -0.25(-0.11%)
Will BIIB be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BIIB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIIB
Why Is Biogen (BIIB) Up 7.7% Since Last Earnings Report?
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
BIIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
Other News for BIIB
Parnassus Value Equity Fund Q1 2024 Investment Commentary
Biogen’s Strategic Diversification and Financial Strategy Garner Outperform Rating
Strategic Acquisitions and Clinical Catalysts Bolster Biogen’s Buy Rating
Biotech Alert: Searches spiking for these stocks today
Biogen (BIIB) Gets a Buy from Oppenheimer